BlackRock Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$141M Buy
2,253,908
+45,191
+2% +$2.76M 0.14% 158
2016
Q3
$139M Sell
2,208,717
-893,905
-29% -$57.9M 0.14% 166
2016
Q2
$192M Sell
3,102,622
-2,387,643
-43% -$145M 0.2% 119
2016
Q1
$314M Sell
5,490,265
-1,866,173
-25% -$104M 0.33% 80
2015
Q4
$436M Sell
7,356,438
-4,443,307
-38% -$256M 0.46% 51
2015
Q3
$642M Sell
11,799,745
-2,892,179
-20% -$188M 0.69% 29
2015
Q2
$987M Buy
14,691,924
+1,067,296
+8% +$69.7M 1.03% 11
2015
Q1
$798M Sell
13,624,628
-1,416,640
-9% -$85.6M 0.82% 19
2014
Q4
$984M Sell
15,041,268
-1,708,880
-10% -$108M 0.99% 13
2014
Q3
$967M Sell
16,750,148
-53,681
-0.3% -$2.98M 0.96% 13
2014
Q2
$948M Buy
16,803,829
+1,336,913
+9% +$70.1M 0.9% 16
2014
Q1
$795M Sell
15,466,916
-947,953
-6% -$47.9M 0.78% 24
2013
Q4
$867M Sell
16,414,869
-311,327
-2% -$15.3M 0.83% 19
2013
Q3
$748M Buy
16,726,196
+1,845,537
+12% +$81.8M 0.75% 18
2013
Q2
$615M Buy
+14,880,659
New +$651M 0.65% 30

Other funds holding ABBV

BlackRock Advisors's ABBV Position: Q4 2016 in Review

BlackRock Advisors increased its AbbVie (ABBV) stake by 2% in Q4 2016, buying an estimated $2.76M and bringing the position to 2,253,908 shares worth $141M. The position accounts for 0.14% of the portfolio, ranked #158.

BlackRock Advisors first reported a position in ABBV in Q2 2013 and has held it in 15 quarters since. The position peaked at $987M in Q2 2015. 1,691 funds tracked by Wall St. Rank hold ABBV as of Q4 2016.

  • BlackRock Advisors held 2,253,908 shares of AbbVie worth $141M as of Q4 2016.
  • BlackRock Advisors bought 45,191 AbbVie shares in Q4 2016, an estimated $2.76M.
  • AbbVie made up 0.14% of BlackRock Advisors's portfolio in Q4 2016, its #158 holding.
  • BlackRock Advisors first reported a position in AbbVie in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's AbbVie position peaked at $987M in Q2 2015.
  • 1,691 funds tracked by Wall St. Rank held AbbVie as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.